Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Active not recruiting 12Recruiting 5Withdrawn 1Suspended 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Other solid neoplasm 1

Conditions

Kidney Neoplasms 2Carcinoma, Renal Cell 2Metastatic Urothelial Cancer 1Lung Diseases 1Erythrocytosis, Familial, 4 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1

Interventions

Specimen Handling 311Magnetic Resonance Spectroscopy 266pembrolizumab 251Carboplatin 184Cyclophosphamide 176Biopsy 172Cisplatin 157Gemcitabine 134Paclitaxel 131Bevacizumab 124fludarabine 117Radiotherapy 108Nivolumab 108Oxaliplatin 88Docetaxel 87Fluorouracil 85Capecitabine 83venetoclax 82Dexamethasone 77Pemetrexed 72Rituximab 71Leucovorin 69Drug Therapy 69atezolizumab 67durvalumab 66Radiosurgery 65Blood Specimen Collection 65Standard of Care 63Doxorubicin 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × zimberelimab × 90 days × Clear all
NCT05536141 2026-06-01

ARC-20

Arcus Biosciences, Inc.

Phase 1 Recruiting
362 enrolled
Genitourinary

Erythrocytosis, Familial, 4, Carcinoma, Renal Cell, Kidney Neoplasms

NCT06431633 2026-05-18

ARIAN

Fundación GECP

Phase 3 Recruiting
129 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases

NCT06532565 2026-04-21

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

Gilead Sciences

Phase 1 Recruiting
154 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT07397611 2026-03-20

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Dana-Farber Cancer Institute

Phase 2 Recruiting
32 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting
827 enrolled 1 FDA
Genitourinary

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡